Antoaneta A. Markova

649 total citations
16 papers, 509 citations indexed

About

Antoaneta A. Markova is a scholar working on Hepatology, Epidemiology and Immunology. According to data from OpenAlex, Antoaneta A. Markova has authored 16 papers receiving a total of 509 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Hepatology, 11 papers in Epidemiology and 4 papers in Immunology. Recurrent topics in Antoaneta A. Markova's work include Hepatitis C virus research (10 papers), Liver Disease Diagnosis and Treatment (8 papers) and Liver Disease and Transplantation (4 papers). Antoaneta A. Markova is often cited by papers focused on Hepatitis C virus research (10 papers), Liver Disease Diagnosis and Treatment (8 papers) and Liver Disease and Transplantation (4 papers). Antoaneta A. Markova collaborates with scholars based in Germany, Poland and United States. Antoaneta A. Markova's co-authors include Markus Cornberg, Michael P. Manns, Heiner Wedemeyer, Kerstin Port, Verena Schlaphoff, Birgit Bremer, Jan Grabowski, Jerzy Jaroszewicz, Katja Deterding and Benjamin Maasoumy and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Hepatology.

In The Last Decade

Antoaneta A. Markova

15 papers receiving 503 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Antoaneta A. Markova Germany 9 442 306 129 103 18 16 509
Chia Wang United States 6 364 0.8× 345 1.1× 58 0.4× 72 0.7× 11 0.6× 11 450
W.O. Böcher Germany 8 279 0.6× 315 1.0× 51 0.4× 110 1.1× 46 2.6× 17 374
Paraskevi Fytili Germany 9 307 0.7× 162 0.5× 120 0.9× 175 1.7× 9 0.5× 15 457
Norma D. Churchill Canada 14 328 0.7× 420 1.4× 59 0.5× 95 0.9× 6 0.3× 17 479
Yoshitaka Etoh Japan 11 368 0.8× 308 1.0× 55 0.4× 27 0.3× 30 1.7× 19 422
Arleta Kowala‐Piaskowska Poland 12 220 0.5× 203 0.7× 52 0.4× 109 1.1× 16 0.9× 56 376
James R. Burton United States 9 441 1.0× 304 1.0× 125 1.0× 143 1.4× 53 2.9× 11 564
C. Sarrazin Germany 14 518 1.2× 522 1.7× 151 1.2× 29 0.3× 42 2.3× 83 637
Uta Naumann Germany 12 575 1.3× 578 1.9× 70 0.5× 30 0.3× 17 0.9× 32 680
T. Santantonio Italy 8 677 1.5× 656 2.1× 74 0.6× 22 0.2× 16 0.9× 17 709

Countries citing papers authored by Antoaneta A. Markova

Since Specialization
Citations

This map shows the geographic impact of Antoaneta A. Markova's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Antoaneta A. Markova with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Antoaneta A. Markova more than expected).

Fields of papers citing papers by Antoaneta A. Markova

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Antoaneta A. Markova. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Antoaneta A. Markova. The network helps show where Antoaneta A. Markova may publish in the future.

Co-authorship network of co-authors of Antoaneta A. Markova

This figure shows the co-authorship network connecting the top 25 collaborators of Antoaneta A. Markova. A scholar is included among the top collaborators of Antoaneta A. Markova based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Antoaneta A. Markova. Antoaneta A. Markova is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Bulut, Kerem, Antoaneta A. Markova, Ali Canbay, Wolfgang E. Schmidt, & Alişan Kahraman. (2022). Whipple’s disease – a rare and challenging complication in a patient with Crohn’s disease. Zeitschrift für Gastroenterologie. 60(4). 598–601. 2 indexed citations
2.
Theysohn, Jens, Matthias Buechter, Katharina Willuweit, et al.. (2022). FIB-4 and APRI as Predictive Factors for Short- and Long-Term Survival in Patients with Transjugular Intrahepatic Portosystemic Stent Shunts. Biomedicines. 10(5). 1018–1018. 1 indexed citations
3.
Bucsics, Theresa, Antoaneta A. Markova, Tammo Lambert Tergast, et al.. (2021). Low Serum Cholinesterase Identifies Patients With Worse Outcome and Increased Mortality After TIPS. Hepatology Communications. 6(3). 621–632. 5 indexed citations
4.
Markova, Antoaneta A., Katja Deterding, Kerstin Port, et al.. (2020). Liver stiffness across different chronic liver disease under therapy with statin in a real life cohort. European Journal of Gastroenterology & Hepatology. 32(2). 223–229. 2 indexed citations
5.
Markova, Antoaneta A., et al.. (2016). Aseptic arthritis due to parvovirus B19 infection immediately after kidney and pancreas transplantation. SHILAP Revista de lepidopterología. 1(3-4). 15–17.
6.
Rogalska, Magdalena, Antoaneta A. Markova, A Taranta, et al.. (2015). Altered effector functions of NK cells in chronic hepatitis C are associated with IFNL3 polymorphism. Journal of Leukocyte Biology. 98(2). 283–294. 8 indexed citations
7.
Maasoumy, Benjamin, Kerstin Port, Katja Deterding, et al.. (2014). Limited effectiveness and safety profile of protease inhibitor-based triple therapy against chronic hepatitis C in a real-world cohort with a high proportion of advanced liver disease. European Journal of Gastroenterology & Hepatology. 26(8). 836–845. 17 indexed citations
8.
Markova, Antoaneta A., Ulrike Mihm, Verena Schlaphoff, et al.. (2014). PEG-IFN Alpha but Not Ribavirin Alters NK Cell Phenotype and Function in Patients with Chronic Hepatitis C. PLoS ONE. 9(4). e94512–e94512. 20 indexed citations
9.
Lunemann, Sebastian, David F. G. Malone, Julia Hengst, et al.. (2013). Compromised Function of Natural Killer Cells in Acute and Chronic Viral Hepatitis. The Journal of Infectious Diseases. 209(9). 1362–1373. 99 indexed citations
10.
Maasoumy, Benjamin, Kerstin Port, Antoaneta A. Markova, et al.. (2013). 857 TRIPLE THERAPY FOR HEPATITIS C VIRUS (HCV) INFECTION IN PATIENTS WITH COMPENSATED LIVER CIRRHOSIS: LESSONS LEARNED FROM THE FIRST REAL-WORLD EXPERIENCE. Journal of Hepatology. 58. S351–S351. 2 indexed citations
11.
Maasoumy, Benjamin, Kerstin Port, Antoaneta A. Markova, et al.. (2013). Eligibility and Safety of Triple Therapy for Hepatitis C: Lessons Learned from the First Experience in a Real World Setting. PLoS ONE. 8(2). e55285–e55285. 81 indexed citations
12.
Maasoumy, Benjamin, Kerstin Port, Antoaneta A. Markova, et al.. (2013). The clinical significance of drug–drug interactions in the era of direct‐acting anti‐viral agents against chronic hepatitis C. Alimentary Pharmacology & Therapeutics. 38(11-12). 1365–1372. 32 indexed citations
13.
Pischke, Sven, Verena Schlaphoff, Jan Grabowski, et al.. (2012). HEV-specific T-cell responses are associated with control of HEV infection. Zeitschrift für Gastroenterologie. 50(1). 12 indexed citations
14.
Suneetha, Pothakamuri Venkata, Sven Pischke, Verena Schlaphoff, et al.. (2011). Hepatitis E virus (HEV)-specific T-cell responses are associated with control of HEV infection. Hepatology. 55(3). 695–708. 131 indexed citations
15.
Jaroszewicz, Jerzy, Antoaneta A. Markova, Katja Deterding, et al.. (2011). Hepatitis B Surface Antigen (Hbsag) Decrease and Serum Interferon-Inducible Protein-10 Levels as Predictive Markers for Hbsag Loss during Treatment with Nucleoside/Nucleotide Analogues. Antiviral Therapy. 16(6). 915–924. 74 indexed citations
16.
Manns, Michael P., Antoaneta A. Markova, Beatriz Calle Serrano, & Markus Cornberg. (2011). Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1. Liver International. 32(s1). 27–31. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Chia Wang Breakdown of academic impact, for papers by W.O. Böcher Breakdown of academic impact, for papers by Paraskevi Fytili Breakdown of academic impact, for papers by Norma D. Churchill Breakdown of academic impact, for papers by Yoshitaka Etoh Breakdown of academic impact, for papers by Arleta Kowala‐Piaskowska Breakdown of academic impact, for papers by James R. Burton Breakdown of academic impact, for papers by C. Sarrazin Breakdown of academic impact, for papers by Uta Naumann Breakdown of academic impact, for papers by T. Santantonio
Rankless by CCL
2026